- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ID Week 2024: Key Updates in UTIs
Wendy Cheng, PhD, MPH, discusses how recent research presented at ID Week 2024, including the EAGLE-2 and EAGLE-3 trials on gepotidacin, highlights new treatment options for urinary tract infections (UTIs), addressing unmet needs and the growing challenge of antimicrobial resistance.
EP. 1: Unmet Needs in the Management of UTIs
December 23rd 2024Wendy Cheng, PhD, MPH, discusses how the largest unmet needs in the landscape of urinary tract infections (UTIs) include addressing antimicrobial resistance, improving treatment options for resistant strains, and developing novel therapies to fill gaps in current UTI management.
Watch
EP. 2: Gepotidacin vs Nitrofurantoin in uUTI: Study Overview and Clinical Implications
January 3rd 2025Wendy Cheng, PhD, MPH, discusses how the study on the efficacy of gepotidacin vs nitrofurantoin in a nitrofurantoin-resistant population (a pooled analysis of the EAGLE-2 and EAGLE-3 trials) aimed to evaluate the effectiveness of gepotidacin as a first-in-class oral therapy for uncomplicated urinary tract infections (uUTIs), showing promising results in overcoming antimicrobial resistance and potentially filling critical gaps in current UTI treatments.
Watch
